FORTISSIMO study
Benefits of the treatment of uncontrolled
hypertension by perindopril/indapamide fixed
full-dose combination
1
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
Objectives
 Evaluate the safety and efficacy of the fixed-dose
combination perindopril arginine/indapamide (10/2.5 mg)
in reaching the blood pressure target
 In patients with uncontrolled hypertension
 With previous treatment: fixed or free combination of
renin-angiotensin-aldosterone system (RAAS) inhibitors +
hydrochlorothiazide (HCTZ)
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
2
Design and Methods
 Open, prospective, multicenter, observational,
noncomparative study
 Inclusion criteria: uncontrolled hypertension (160-200
mm Hg)
 2120 hypertensive ambulatory patients in 35 regions of
Russia
 12-week study (5 visits)
 Switch to drug combination perindopril/indapamide
(10/2.5 mg)
 Assessment of:
̶
̶
̶
̶
Office blood pressure dynamics
Blood and urine assays
Quality of life
Treatment compliance
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
3
Results – Blood pressure
 Blood pressure significantly decreased over time
 After 3 months of treatment, 84% of patients reached the
blood pressure target
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
4
Results - Tolerability
 Treatment compliance significantly increased
 Only 4% of patients had adverse effects
 Biochemical markers showed no negative changes
7
6
mmol/L
5
5.35 5.14
5.84
At baseline
5.18
4.34 4.33
4
3.28
3
2.82
After 3 months of
treatment
1.36 1.41
2
1.75 1.56
1
0
K+
Glucose
Total
cholesterol
Low-density
lipoprotein
cholesterol
High-density
lipoprotein
cholesterol
Triglycerides
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
5
Conclusion
 Rapid and sustained effect with the drug combination
perindopril/indapamide (10/2.5 mg) in patients with
uncontrolled hypertension
 84% of patients reached the blood pressure target
 Treatment: good tolerability
Karpov YA; FORTISSIMO program. Poster presented at: European Society of Hypertension Congress; June 14-17, 2013; Milan, Italy.
6